Lanthanum Viatris (Lanthanum)

Lanthanum carbonate releases lanthanum ions in the acidic stomach environment. These ions bind dietary phosphate to form insoluble lanthanum phosphate complexes that are not absorbed. The complexes are excreted in the feces, reducing the amount of phosphate that enters the bloodstream and thereby lowering serum phosphate concentrations.

The dose of Lanthanum Viatris is individualized by the prescribing clinician based on the patient’s serum phosphate levels, dietary phosphate intake, and overall renal function. The prescriber will adjust the amount and frequency of tablets to achieve target phosphate concentrations while minimizing side effects.

Safety data for Lanthanum Viatris in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Lanthanum Viatris product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lanthanum Viatris is a non‑calcium, non‑aluminum phosphate binder, offering an alternative to calcium‑based binders that can increase calcium load. Compared with sevelamer, lanthanum generally has a lower pill burden but may cause more gastrointestinal discomfort. Choice of binder depends on individual patient factors such as calcium balance, tolerance, and cost considerations.

Lanthanum Viatris should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and efficacy throughout its shelf life.

Lanthanum Viatris is taken orally, usually as tablets taken with meals to maximize phosphate binding. The tablets should be swallowed whole with a sufficient amount of water and not chewed or crushed, unless the prescriber provides specific instructions for alternative administration.

Serious adverse events, although rare, include severe constipation or intestinal obstruction, significant hypophosphatemia, and allergic reactions that may manifest as rash, itching, or anaphylaxis. Patients should be monitored for these conditions, and therapy should be discontinued promptly if any serious reaction occurs.

Lanthanum Viatris should be avoided in individuals with known hypersensitivity to lanthanum or any component of the formulation, in patients with existing severe gastrointestinal obstruction, and in those for whom a calcium‑based binder is clinically preferred. Use in pediatric patients is not established and should be considered only under specialist guidance.